Secondary cytoreduction for relapsed ovarian cancer - Authors' reply

Affiliations

¹ Ovarian Cancer Program, Department of Gynaecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
² Department of Gynaecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Sun Yat-sen University Cancer Centre, Guangzhou, China.
³ Department of Gynaecologic Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
⁴ Ovarian Cancer Program, Department of Gynaecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Electronic address: zang.rongyu@zs-hospital.sh.cn.

Comment

Yulian Chen et al. Lancet Oncol. 2021 Jun.

. 2021 Jun;22(6):e233.

doi: 10.1016/S1470-2045(21)00294-1.

¹ Ovarian Cancer Program, Department of Gynaecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
² Department of Gynaecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Sun Yat-sen University Cancer Centre, Guangzhou, China.
³ Department of Gynaecologic Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
⁴ Ovarian Cancer Program, Department of Gynaecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Electronic address: zang.rongyu@zs-hospital.sh.cn.

No abstract available

Conflict of interest statement

We declare no competing interests.

Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, Jia H, Huang X, Cai Y, Yin S, Jiang R, Tian W, Gao W, Liu J, Yang H, Cheng X, Zang R. Shi T, et al. Lancet Oncol. 2021 Apr;22(4):439-449. doi: 10.1016/S1470-2045(21)00006-1. Epub 2021 Mar 8. Lancet Oncol. 2021. PMID: 33705695 Clinical Trial.
Secondary cytoreduction for relapsed ovarian cancer.
Garg PK, Kumar R, Choudhary D. Garg PK, et al. Lancet Oncol. 2021 Jun;22(6):e230. doi: 10.1016/S1470-2045(21)00181-9. Lancet Oncol. 2021. PMID: 34087139 No abstract available.
Secondary cytoreduction for relapsed ovarian cancer.
Carneiro VCG, Ramalho NM. Carneiro VCG, et al. Lancet Oncol. 2021 Jun;22(6):e231. doi: 10.1016/S1470-2045(21)00187-X. Lancet Oncol. 2021. PMID: 34087140 No abstract available.
Secondary cytoreduction for relapsed ovarian cancer.
Iannantuono GM, Giudice E. Iannantuono GM, et al. Lancet Oncol. 2021 Jun;22(6):e232. doi: 10.1016/S1470-2045(21)00277-1. Lancet Oncol. 2021. PMID: 34087141 No abstract available.